Event: ESMO AI and Digital Oncology Congress 2026
Dates: November 16-18, 2026
City: Berlin, Germany
Organizer: European Society for Medical Oncology (ESMO)
About the event
ESMO runs the big European cancer congresses, and this is its dedicated meeting on AI and digital tools in oncology: pathology models, genomics, clinical decision support and the data infrastructure behind them. The audience is oncologists, computational biologists and the companies selling diagnostic AI into hospitals and drug developers.
BostonGene’s presentations
Oral, Abstract 252, November 16, 3:15-4:00 pm, Alpha 1. Aleksandr Sarachakov, PhD, presents “Resolving tumor-of-origin from incomplete clinical data: a multimodal AI framework integrating histopathology, transcriptomics, and genomics”. Built with Weill Cornell Medicine, the framework predicts where a tumor came from in cancer of unknown primary (CUP), even from partial diagnostic profiles. CUP patients often can’t get a matching therapy or join a trial until the origin is known, so faster answers matter.
Poster, Abstract 376, November 17, 4:30-5:30 pm. Alexander Bagaev, PhD, presents “Deconvolving bulk tumor transcriptomes: A Pan-Cancer Deep Learning Approach”. The model splits bulk RNA-seq data across 20 tumor microenvironment cell types and 13 tumor diagnoses, producing more than 14,000 compartment-specific expression profiles. With Inova Schar Cancer Institute and Endeavor Health, it separated gene expression in tumor cells from expression in the surrounding microenvironment, which BostonGene says reduces target ambiguity for drug developers.
Who should go
Oncologists and pathologists evaluating AI tools, translational researchers, and diagnostics and pharma teams working on biomarkers and target discovery.